Helix Biopharma Corp Stock Performance
| HBPCF Stock | USD 1.73 0.00 0.00% |
Helix BioPharma holds a performance score of 10 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of -4.64, which attests to a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Helix BioPharma are expected to decrease by larger amounts. On the other hand, during market turmoil, Helix BioPharma is expected to outperform it. Use Helix BioPharma Corp variance, maximum drawdown, as well as the relationship between the Maximum Drawdown and rate of daily change , to analyze future returns on Helix BioPharma Corp.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Helix BioPharma Corp are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental indicators, Helix BioPharma reported solid returns over the last few months and may actually be approaching a breakup point. ...more
Helix |
Helix BioPharma Relative Risk vs. Return Landscape
If you would invest 60.00 in Helix BioPharma Corp on September 28, 2025 and sell it today you would earn a total of 113.00 from holding Helix BioPharma Corp or generate 188.33% return on investment over 90 days. Helix BioPharma Corp is currently producing 2.9894% returns and takes up 23.7278% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Helix, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Helix BioPharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Helix BioPharma's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Helix BioPharma Corp, and traders can use it to determine the average amount a Helix BioPharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | |||
| Good Returns | HBPCF | |||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Helix BioPharma is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Helix BioPharma by adding it to a well-diversified portfolio.
Helix BioPharma Fundamentals Growth
Helix Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Helix BioPharma, and Helix BioPharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Helix Pink Sheet performance.
| Return On Equity | -12.06 | |||
| Return On Asset | -1.04 | |||
| Current Valuation | 30.65 M | |||
| Shares Outstanding | 200.02 M | |||
| Price To Earning | (6.52) X | |||
| Price To Book | 134.72 X | |||
| EBITDA | (6.53 M) | |||
| Cash And Equivalents | 1.88 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.88 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (6.51 M) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 3.73 M | |||
| Current Asset | 22.72 M | |||
| Current Liabilities | 2.32 M | |||
About Helix BioPharma Performance
By analyzing Helix BioPharma's fundamental ratios, stakeholders can gain valuable insights into Helix BioPharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Helix BioPharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Helix BioPharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Helix BioPharma Corp. operates as an immune-oncology company in Canada. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors and with ProMab Biotechnologies, Inc. to develop novel antibody and chimeric antigen receptor T-cell therapy to treat multiple myeloma, as well as a license agreements with Xisle Pharma Ventures Trust and National Research of Council Canada. HELIX BIOPHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 10 people.Things to note about Helix BioPharma Corp performance evaluation
Checking the ongoing alerts about Helix BioPharma for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Helix BioPharma Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Helix BioPharma Corp is way too risky over 90 days horizon | |
| Helix BioPharma Corp may become a speculative penny stock | |
| Helix BioPharma Corp appears to be risky and price may revert if volatility continues | |
| Helix BioPharma Corp has accumulated 2.88 M in total debt with debt to equity ratio (D/E) of 0.03, which may suggest the company is not taking enough advantage from borrowing. Helix BioPharma Corp has a current ratio of 0.68, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Helix BioPharma until it has trouble settling it off, either with new capital or with free cash flow. So, Helix BioPharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Helix BioPharma Corp sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Helix to invest in growth at high rates of return. When we think about Helix BioPharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (6.56 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Helix BioPharma Corp has accumulated about 1.88 M in cash with (6.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 18.0% of Helix BioPharma shares are held by company insiders |
- Analyzing Helix BioPharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Helix BioPharma's stock is overvalued or undervalued compared to its peers.
- Examining Helix BioPharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Helix BioPharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Helix BioPharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Helix BioPharma's pink sheet. These opinions can provide insight into Helix BioPharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Helix Pink Sheet analysis
When running Helix BioPharma's price analysis, check to measure Helix BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Helix BioPharma is operating at the current time. Most of Helix BioPharma's value examination focuses on studying past and present price action to predict the probability of Helix BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Helix BioPharma's price. Additionally, you may evaluate how the addition of Helix BioPharma to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |